STOCK TITAN

Centrus Reports First Quarter 2026 Results

Rhea-AI Impact
(Very High)
Rhea-AI Sentiment
(Neutral)
Tags

Centrus (NYSE: LEU) reported Q1 2026 results: revenue $76.7M, GAAP net income $10.0M, and non-GAAP adjusted net income $23.5M. The company launched a multi-year centrifuge manufacturing expansion in Oak Ridge, signed Fluor and Palantir partnerships, and raised 2026 revenue guidance to $450M–$500M.

Backlog totaled $3.9B extending to 2040; full-year capital deployment guidance is $350M–$500M.

Loading...
Loading translation...

Positive

  • Revenue increased to $76.7M in Q1 2026 (+5% YoY)
  • Non-GAAP adjusted net income of $23.5M in Q1 2026
  • Backlog of $3.9B extending to 2040
  • Raised 2026 consolidated revenue guidance to $450M–$500M
  • Launched multi-year centrifuge manufacturing expansion in Oak Ridge

Negative

  • GAAP net income declined to $10.0M from $27.2M (Q1 2025)
  • LEU segment revenue fell 13% to $44.6M
  • Advanced technology costs increased by $15.9M
  • Total capital deployment guidance of $350M–$500M increases near-term cash needs

Key Figures

Q1 2026 revenue: $76.7 million Q1 2025 revenue: $73.1 million Q1 2026 GAAP net income: $10.0 million +5 more
8 metrics
Q1 2026 revenue $76.7 million Three months ended March 31, 2026
Q1 2025 revenue $73.1 million Three months ended March 31, 2025
Q1 2026 GAAP net income $10.0 million Three months ended March 31, 2026
Q1 2025 GAAP net income $27.2 million Three months ended March 31, 2025
Q1 2026 adjusted net income $23.5 million Non-GAAP adjusted, three months ended March 31, 2026
Backlog total $3.9 billion Backlog across both segments as of March 31, 2026
2026 revenue guidance $450–500 million Upward revision from $425–475 million
2026 capital deployment $350–500 million Total capital deployment guidance for 2026

Market Reality Check

Price: $206.92 Vol: Volume 883,985 is close t...
normal vol
$206.92 Last Close
Volume Volume 883,985 is close to the 20-day average of 912,287 (relative volume 0.97x). normal
Technical Shares at 206.04 trade below the 251.94 200-day MA and sit 55.62% under the 52-week high of 464.25.

Peers on Argus

LEU was up 0.14% while key uranium peers CCJ, NXE, UUUU, UEC, and DNN were all d...

LEU was up 0.14% while key uranium peers CCJ, NXE, UUUU, UEC, and DNN were all down between about 3–6%, indicating stock-specific resilience versus sector pressure.

Common Catalyst Multiple uranium names, including CCJ, had earnings-related headlines, suggesting broader sector news flow even as LEU’s price direction diverged.

Previous Earnings Reports

5 past events · Latest: Feb 10 (Positive)
Same Type Pattern 5 events
Date Event Sentiment Move Catalyst
Feb 10 Full-year 2025 earnings Positive -20.7% Reported 2025 growth, strong backlog, cash build and issued 2026 guidance.
Nov 05 Q3 2025 earnings Positive -14.7% Improved revenue and net income, major note offering and solid backlog.
Aug 05 Q2 2025 earnings Positive +8.7% Strong results, 900 kg HALEU delivery and DOE option valued at $110M.
May 07 Q1 2025 earnings Positive +22.0% Strong Q1 swing to profit, higher LEU revenue and $3.8B backlog.
Feb 06 Full-year 2024 earnings Positive +33.1% Revenue growth, solid net income, note issuance and $3.7B backlog.
Pattern Detected

Earnings releases have generally been positive in tone, with three prior reports seeing strong gains and two showing sharp selloffs despite constructive fundamentals.

Recent Company History

Recent earnings news has emphasized revenue growth, rising backlog, and major DOE-linked HALEU and LEU contracts. Prior quarters featured sizeable net income, multi‑billion‑dollar backlogs up to $3.9 billion, and large financing moves including convertible notes and ATM equity. Price reactions have been mixed: some earnings reports triggered strong rallies, while others sold off despite positive headlines and guidance. Today’s Q1 2026 update, with higher revenue but lower net income and raised 2026 guidance, fits into this pattern of significant, sometimes volatile responses around earnings.

Historical Comparison

+5.7% avg move · Past earnings releases often featured strong revenue, backlog and contract wins, with average moves ...
earnings
+5.7%
Average Historical Move earnings

Past earnings releases often featured strong revenue, backlog and contract wins, with average moves of 5.69%. Reactions swung between sharp rallies and selloffs despite broadly constructive updates.

Earnings updates show progression from 2024–2025 balance sheet strengthening and backlog growth to 2026 guidance increases and expanded HALEU and LEU capacity plans.

Regulatory & Risk Context

Active S-3 Shelf
Shelf Active
Active S-3 Shelf Registration 2025-11-06

Centrus has an effective automatic shelf registration on Form S-3ASR filed on 2025-11-06, allowing it to issue various securities, including common and preferred stock, debt, warrants, rights, and units, via future prospectus supplements for general corporate purposes.

Market Pulse Summary

This announcement combines modest Q1 revenue growth with lower net income, but highlights a substant...
Analysis

This announcement combines modest Q1 revenue growth with lower net income, but highlights a substantial $3.9 billion backlog and an upward revision of 2026 revenue guidance to $450–500 million. Segment detail underscores growing Technical Solutions contributions and ongoing HALEU contract work, while LEU results remain timing-sensitive. Key swing factors include execution of major expansion projects, negotiation and funding of the DOE $900 million task order, and managing rising capital deployment against future cash needs.

Key Terms

gaap, non-gaap, high-assay, low-enriched uranium (haleu), cost-plus-incentive-fee, +3 more
7 terms
gaap financial
"GAAP net income of $10.0 million compared to GAAP net income..."
GAAP, or Generally Accepted Accounting Principles, are a set of standardized rules and guidelines that companies follow when preparing their financial statements. They ensure consistency, transparency, and comparability across different companies, making it easier for investors to understand and compare financial information accurately. This helps investors make informed decisions based on trustworthy and uniform financial reports.
non-gaap financial
"Non-GAAP adjusted net income (1) of $23.5 million, compared to..."
Non-GAAP refers to financial measures that companies use to show their earnings or performance without including certain expenses or income that are often added back to give a different picture. It matters because it can make a company's results look better or more favorable, but it may also hide important costs, so investors need to look at both GAAP (official rules) and non-GAAP numbers to get a full understanding.
high-assay, low-enriched uranium (haleu) medical
"deconversion services for high-assay, low-enriched uranium (HALEU)"
High-assay, low-enriched uranium (HALEU) is a form of nuclear fuel that contains a higher concentration of the fissile isotope U-235 than conventional reactor fuel but remains well below weapons-grade levels. Investors care because HALEU is needed by many advanced and small modular reactors; think of it like higher-octane gasoline for new engines — limited supply, special handling, and regulatory oversight can affect project timelines, costs and the value of companies in the nuclear energy supply chain.
cost-plus-incentive-fee financial
"Revenue from the HALEU Operation Contract is recorded on a cost-plus-incentive-fee basis..."
A cost-plus-incentive-fee contract pays a supplier back for its actual costs and adds a variable bonus or penalty based on how closely the final cost matches an agreed target. Think of it like covering a contractor’s receipts plus a reward if they finish under budget (or a reduced bonus if they go over). For investors, this structure affects how predictable revenue and profit are and creates both upside if cost control succeeds and downside if expenses run high.
backlog financial
"The Company's backlog across both segments is $3.9 billion as of March 31, 2026..."
A backlog is the amount of work or orders that a company has received but hasn't completed yet. It’s like a restaurant with many dishes to serve; the backlog shows how many orders are still waiting to be finished. It matters because a large backlog can indicate strong demand or potential delays in delivering products or services.
task order regulatory
"including the finalization and funding of the DOE $900 million task order"
A task order is a specific request for work or services issued under an existing contract, telling a supplier what to deliver, when, and for how much. For investors, task orders matter because they convert a broad contract promise into real, billable work—like adding items to a standing shopping list—and so winning or delivering task orders can directly affect a company’s near-term revenue and cash flow visibility.
phase 2 technical
"Because of the delay in completing Phase 2 of the HALEU Operation Contract..."
Phase 2 is the mid-stage clinical trial where a new drug or treatment is tested in a larger group of patients to see if it works and to keep checking safety after initial human testing. Think of it as a field test that proves whether a product actually delivers its promised benefit. Investors watch Phase 2 closely because its results strongly influence a medicine’s chances of reaching the market, the size of its potential sales, and the company’s valuation.

AI-generated analysis. Not financial advice.

  • Revenue of $76.7 million, compared to revenue of $73.1 million in Q1 2025
  • GAAP net income of $10.0 million compared to GAAP net income of $27.2 million in Q1 2025
  • Non-GAAP adjusted net income (1) of $23.5 million, compared to non-GAAP adjusted net income(1) of $28.6 million in Q1 2025
  • Launched multi-year investment in Oak Ridge, Tennessee, to expand and accelerate centrifuge manufacturing program
  • Signed strategic collaboration with Fluor to oversee engineering, design, project management, supply chain activities, and procurement of key materials and services on plant expansion
  • Partnered with Palantir to leverage its artificial intelligence platform; early work identified ~$300 million in potential costs savings and additional improvements expected to reduce manufacturing lead times and accelerate expansion's timetable
  • Exploring joint-venture with Oklo focused on deconversion services for high-assay, low-enriched uranium (HALEU)
  • Raising full year 2026 revenue guidance based on commercial progress

BETHESDA, Md., May 5, 2026 /PRNewswire/ -- Centrus Energy Corp. (NYSE: LEU) ("Centrus" or the "Company") today reported first quarter 2026 results. The Company reported net income of $10.0 million for the three months ended March 31, 2026, which is $0.51 (basic) and $0.45 (diluted) per common share. This translates to adjusted net income(1) of $23.5 million for the three months ended March 31, 2026, which is adjusted EPS(1) of $1.19 (basic) and $1.05 (diluted) per common share.

"The first quarter was marked by numerous wins and great operational progress as we accelerated our drive to restore America's ability to enrich uranium at scale, including securing historic federal funding and launching a major expansion of our centrifuge manufacturing plant," said Centrus President and CEO Amir Vexler.

"We have now switched to full execution mode to accelerate our build-out while building a best-in-class partnership network, including Palantir, Fluor, and Geiger Brothers, as part of our day-one focus to reduce costs and bring in lead times. We've already identified approximately $300 million in cost reductions as well as opportunities to both reduce manufacturing lead times and accelerate our timetable. Going forward we will continue to unleash our network's full capabilities, including Palantir's leading artificial intelligence platform, to unlock more efficiency gains.

"Our expansion is well timed. Global conflicts and rising tensions continue to highlight the need to diversify away from fossil fuels towards domestic power sources to drive future sustainable economic growth."

(1)A reconciliation of non-GAAP results are detailed in the Financial Results section. Additional information can be found in the materials on the Centrus investor relations website at https://investors.centrusenergy.com.

Financial Results

Centrus generated total revenue of $76.7 million and $73.1 million for the three months ended March 31, 2026 and 2025, respectively, an increase of $3.6 million (or 5%).

Revenue from the LEU segment was $44.6 million and $51.3 million for the three months ended March 31, 2026 and 2025, respectively, a decrease of $6.7 million (or 13%). Separative work units (SWU) revenue decreased by $9.7 million as a result of a 47% decrease in the volume of SWU sold, partially offset by a 52% increase in the average price of SWU sold. The Company had uranium revenue of $3.0 million for the three months ended March 31, 2026.

Revenue from the Technical Solutions segment was $32.1 million and $21.8 million for the three months ended March 31, 2026 and 2025, respectively, an increase of $10.3 million (or 47%). The increase in revenue was primarily attributable to a $9.8 million increase in revenue generated by the HALEU production contract with the Department of Energy ("DOE") signed in 2022 ("HALEU Operation Contract"), while the remaining change was generally related to other contracts. Revenue from the HALEU Operation Contract is recorded on a cost-plus-incentive-fee basis and includes a target fee for Phases 2 and 3 of the contract.

Cost of sales for the LEU segment was $16.7 million and $20.1 million for the three months ended March 31, 2026 and 2025, respectively, a decrease of $3.4 million (or 17%). SWU costs decreased as a result of a 47% decrease in the volume of SWU sold, partially offset by a 45% increase in the average unit cost of SWU sold. Uranium costs increased primarily as a result of an increase in the volume of uranium sold.

Cost of sales for the Technical Solutions segment was $28.5 million and $20.1 million for the three months ended March 31, 2026 and 2025, respectively, an increase of $8.4 million (or 42%). The increase was primarily attributable to an $8.2 million increase in costs incurred under the HALEU Operation Contract, while the remaining change was generally attributable to other contracts.

The Company recognized gross profit of $31.5 million and a gross profit of $32.9 million for the three months ended March 31, 2026 and 2025, respectively, a decrease of $1.4 million (or 4%).

Gross profit for the LEU segment was $27.9 million and $31.2 million for the three months ended March 31, 2026 and 2025, respectively, a decrease of $3.3 million (or 11%). LEU customers generally have multi-year contracts that carry annual purchase commitments, not quarterly commitments. The gross profit in our LEU business varies based upon the timing of those contracts. The pricing applied to deliveries varies depending upon the market conditions at the time the contract was signed. The increase for the three months ended March 31, 2026 was primarily due to the composition of contracts in the current quarter, compared to the prior quarter.

Gross profit for the Technical Solutions segment was $3.6 million and $1.7 million for the three months ended March 31, 2026 and 2025, respectively, an increase of $1.9 million (or 112%). Because of the delay in completing Phase 2 of the HALEU Operation Contract, DOE extended the Phase 2 period of performance through October 31, 2025. Costs incurred subsequent to November 2024 have not yet been subject to a fee as this portion of Phase 2 remains undefinitized and is subject to negotiation.

Net income was $10.0 million and $27.2 million for the three months ended March 31, 2026 and 2025, respectively, a decrease of $17.2 million (or 63%). The decrease was primarily attributable to an increase in advanced technology costs of $15.9 million and a decrease in extinguishment of long-term debt of $11.8 million. This decrease was partially offset by an increase of $9.7 million in investment income and a decrease of $5.5 million in income tax expense.

Backlog

The Company's backlog across both segments is $3.9 billion as of March 31, 2026 and extends to 2040. Our LEU segment backlog as of March 31, 2026 is approximately $3.1 billion. The LEU backlog is the estimated aggregate dollar amount of revenue for future SWU and uranium deliveries primarily under medium and long-term contracts with fixed commitments and approximately $2.4 billion in contingent LEU sales commitments, all of which are under definitive agreements, in support of potential construction of LEU production capacity at the Piketon, Ohio facility. The contingent LEU sales commitments also depend on our ability to secure substantial public and private investment. Our Technical Solutions segment backlog is approximately $0.8 billion as of March 31, 2026, and includes both funded amounts (services for which funding has been both authorized and appropriated by the customer), unfunded amounts (services for which funding has not been appropriated), and unexercised options.

2026 Outlook

The Company is updating some of its financial and operational guidance for the full-year 2026 based on information available to the Company at the time of this release.

Financial 2026 Outlook
For the full year 2026, on a consolidated basis, Centrus expects:

  • Upward revised total revenue to be in the range of $450 million to $500 million from $425 million to $475 million
  • Total capital deployment to be in the range of $350 million to $500 million, driven by increased investment in the Company's industrial build out related to its centrifuge manufacturing

Operational 2026 Outlook
For the full year 2026, on a consolidated basis, Centrus expects to:

  • Finalize contracts with all partners identified as critical to its industrial build out
  • At least 100 net new employee hires for Oak Ridge, Tennessee, facility
  • At least 100 net new employee hires for Piketon, Ohio, facility up from 50 net new employee hires
  • Release of a Certified for Construction package

The Company's 2026 guidance is subject to a number of assumptions and uncertainties that could affect results either positively or negatively. Variations from these expectations could cause differences between this guidance and the ultimate results. This includes the assumption of no significant change in restrictions in our ability to receive and sell Russian LEU or other uranium products, no significant economic disruptions or downturns, the successful implementation of our planned expansion projects, including the finalization and funding of the DOE $900 million task order, and that current business operations will continue on an ongoing basis.

About Centrus Energy Corp.

Centrus Energy is a trusted American supplier of nuclear fuel and services for the nuclear power industry, helping meet the growing need for clean, affordable, carbon-free energy. Since 1998, the Company has provided its utility customers with more than 1,850 reactor years of fuel, which is equivalent to more than 7 billion tons of coal.

With world-class technical and engineering capabilities, Centrus is pioneering production of High-Assay, Low-Enriched Uranium and is leading the effort to restore America's uranium enrichment capabilities at scale so that we can meet our clean energy, energy security, and national security needs. Find out more at www.centrusenergy.com or follow us on LinkedIn and X.

Forward-Looking Statements:

This news release contains "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. In this context, forward-looking statements mean statements related to future events, which may impact our expected future business and financial performance, and often contain words such as "expects", "anticipates", "intends", "plans", "believes", "will", "should", "could", "would" or "may" and other words of similar meaning. These forward-looking statements are based on information available to us as of the date of this news release and represent management's current views and assumptions with respect to future events and operational, economic and financial performance. Forward-looking statements are not guarantees of future performance, events or results and involve known and unknown risks, uncertainties and other factors, which may be beyond our control, and which may be exacerbated by any worsening of the global business and economic environment, including but not limited to, risks and uncertainties related to the following:

  • the war in Ukraine and other geopolitical conflicts, including the resulting bans, laws, tariffs, sanctions or other government measures, and actions by third parties, including contractual counterparties, as a result of such conflicts that could directly or indirectly impact our ability to obtain, deliver, transport, sell or collect payment for, LEU or the SWU and natural uranium hexafluoride components of LEU;
  • our reliance on third party suppliers to provide essential products and services to us;
  • restrictions on imports and exports, including those imposed under the RSA, and related international trade legislation;
  • our lease to our facility in Piketon, Ohio and our government contracts, including related to government shutdowns, changes to the U.S. government's appropriated funding levels for HALEU and the government's inability to satisfy its obligations;
  • our receipt of additional task orders under the HALEU Production Contract, LEU Production Contract and HALEU Deconversion Contract and, if awarded, the nature, timing and amount thereof;
  • our ability to obtain new contracts or funding to be able to continue operations;
  • whether or when government demand for HALEU or LEU for government or commercial uses will materialize and at what level;
  • the impact and potential extended duration of a supply/demand imbalance in the market for LEU;
  • significant competition from major LEU producers, including foreign competitors, who may be less cost sensitive than we are;
  • limitations on our ability to compete in foreign markets;
  • pricing trends and demand in the uranium and enrichment markets, especially in light of the potential of limited supply and our dependence on others for deliveries of LEU;
  • our ability to successfully implement our planned expansion projects in Piketon, Ohio and Oak Ridge, Tennessee;
  • our ability to successfully integrate artificial intelligence technologies into our operations;
  • natural and other disasters;
  • pandemics and other health crises;
  • the fact that our revenue is largely dependent on our largest customers and our sales backlog;
  • our long-term liabilities, including our postretirement health and life benefit obligations, our 0% Convertible Notes and our 2.25% Convertible Notes;
  • failures or security, including cybersecurity, breaches of our information technology systems; and
  • the impact of, or changes to, government regulation and policies or interpretation of laws or regulations, including by the U.S. Securities and Exchange Commission, the DOE, the U.S. Department of Commerce, and the U.S. Nuclear Regulatory Commission.

Readers are cautioned not to place undue reliance on these forward-looking statements, which apply only as of the date of this news release. These factors may not constitute all factors that could cause actual results to differ from those discussed in any forward-looking statement. Accordingly, forward-looking statements should not be relied upon as a predictor of actual results. Readers are urged to carefully review and consider the various disclosures made in this news release and in our filings with the SEC, including our Annual Report on Form 10-K for the year ended December 31, 2025, under Part II, Item 1A - "Risk Factors" in our Quarterly report on Form 10-Q for the quarter ended March 31, 2026, and our filings with the SEC that attempt to advise interested parties of the risks and factors that may affect our business. We do not undertake to update our forward-looking statements to reflect events or circumstances that may arise after the date of this news release, except as required by law.

Contacts:

Investors: Neal Nagarajan at NagarajanNK@centrusenergy.com   
Media: Dan Leistikow at LeistikowD@centrusenergy.com

CENTRUS ENERGY CORP.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME
(Unaudited; in millions, except share and per share data) 


Three Months Ended
March 31,


2026


2025

Revenue:




Separative work units

$                       41.6


$                       51.3

Uranium

3.0


Technical solutions

32.1


21.8

Total revenue

76.7


73.1

Cost of Sales:




Separative work units and uranium

16.7


20.1

Technical solutions

28.5


20.1

Total cost of sales

45.2


40.2

Gross profit

31.5


32.9

Advanced technology costs

18.9


3.0

Selling, general and administrative

10.0


8.3

Amortization of intangible assets

1.8


1.1

Operating income

0.8


20.5

Nonoperating components of net periodic benefit loss

1.0


0.9

Interest expense

4.0


3.4

Investment income

(17.0)


(7.3)

Extinguishment of long-term debt


(11.8)

Other expense, net

0.3


0.1

Income before income taxes

12.5


35.2

Income tax expense

2.5


8.0

Net income and comprehensive income

$                       10.0


$                       27.2





Net income per share:




   Basic

$                       0.51


$                       1.60

   Diluted

$                       0.45


$                       1.60

Average number of common shares outstanding (in thousands):




   Basic

19,773


16,982

   Diluted

22,446


17,048

CENTRUS ENERGY CORP.
NON-GAAP ADJUSTED OPERATING INCOME, ADJUSTED NET INCOME AND
ADJUSTED NET INCOME PER SHARE RECONCILIATION TABLE

The Company measures Operating Income, Net Income and Net Income per Share both on a GAAP basis and on an adjusted basis ("Adjusted Operating Income", "Adjusted Net Income" and "Adjusted Net Income per Share") to exclude short-term, non-capitalizable costs related to the expansion of our operations in Piketon, Ohio and Oak Ridge, Tennessee to scale up uranium enrichment operations ("Growth Costs") and stock-based compensation. Growth Costs relate to the initial phase of our expansion projects (e.g. manufacturing readiness and the training and onboarding of new employees) and are included as Advanced Technology Costs on the Condensed Consolidated Statements of Operations and Comprehensive Income. The Company expects to stop expensing Growth Costs as costs related to our expansion projects become capitalizable. We incur expense related to stock-based compensation which are included as Selling, General and Administrative expense on the Condensed Consolidated Statements of Operations and Comprehensive Income.

We believe Adjusted Operating Income, Adjusted Net Income and Adjusted Net Income per Share, which are non-GAAP financial measures, provide investors with additional understanding of the Company's overall financial performance as well as its strategic financial planning analysis and period-to-period comparability. These metrics are useful to investors because they reflect how management evaluates the Company's ongoing operating performance from period-to-period after removing certain transactions and activities that affect comparability of the metrics and are not reflective of the Company's core operations.

Our calculation of Adjusted Operating Income, Adjusted Net Income, and Adjusted Net Income per Share may not be comparable to similarly named measures reported by other companies.


Three Months Ended March 31, 2026


Three Months Ended March 31, 2025


GAAP


Growth
Costs


Stock-
Based
Compen
sation


Adjusted
(Non-
GAAP)


GAAP


Growth
Costs


Stock-
Based
Compen
sation


Adjusted
(Non-
GAAP)

Gross profit

31.5




31.5


32.9




32.9

Advanced technology costs

18.9


(17.0)



1.9


3.0


(1.3)



1.7

Selling, general and administrative

10.0



(0.4)


9.6


8.3



(0.5)


7.8

Amortization of intangible assets

1.8




1.8


1.1




1.1

Operating income

0.8


17.0


0.4


18.2


20.5


1.3


0.5


22.3

Nonoperating components of net
periodic benefit loss

1.0




1.0


0.9




0.9

Interest expense

4.0




4.0


3.4




3.4

Investment income

(17.0)




(17.0)


(7.3)




(7.3)

Extinguishment of long-term
debt





(11.8)




(11.8)

Other expense, net

0.3




0.3


0.1




0.1

Income before income taxes

12.5


17.0


0.4


29.9


35.2


1.3


0.5


37.0

Income tax expense

2.5


3.8


0.1


6.4


8.0


0.3


0.1


8.4

Net income and comprehensive
income

$       10.0


$       13.2


$         0.3


$       23.5


$       27.2


$         1.0


$         0.4


$       28.6

















Net income per share:
















   Basic

$       0.51


$       0.67


$       0.01


$       1.19


$       1.60


$       0.06


$       0.02


$       1.68

   Diluted

$       0.45


$       0.59


$       0.01


$       1.05


$       1.60


$       0.06


$       0.02


$       1.68

Average number of common
shares outstanding (in
thousands):
















   Basic

19,773




19,773


16,982




16,982

   Diluted

22,446




22,446


17,048




17,048

CENTRUS ENERGY CORP.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited; in millions)


Three Months Ended March 31,


2026


2025

OPERATING




Net income

$                       10.0


$                       27.2

Adjustments to reconcile net income to cash used in operating activities:




Depreciation and amortization

2.2


1.5

Deferred tax assets

2.5


7.5

Equity-related compensation

0.4


0.5

Revaluation of inventory borrowings

(0.6)


2.1

Gain on extinguishment of 8.25% Notes


(11.8)

Amortization of debt issuance costs and discount

1.3


Other reconciling adjustments, net

0.3


0.6

Changes in operating assets and liabilities:




Accounts receivable

(11.1)


41.3

Inventories

(48.8)


(268.1)

Inventories owed to customers and suppliers

(21.9)


187.7

Other current assets

(0.6)


0.8

Accounts payable and other liabilities

0.4


(6.2)

Payables under inventory purchase agreements

47.2


55.6

Deferred revenue and advances from customers, net of deferred costs

(14.4)


0.1

Pension and postretirement benefit liabilities

(2.0)


(2.2)

Other changes, net


(0.1)

Cash (used in) provided by operating activities

(35.1)


36.5





INVESTING




Capital expenditures

(23.2)


(2.1)

Cash used in investing activities

(23.2)


(2.1)





FINANCING




Proceeds from the issuance of common stock, net


25.2

Common stock withheld for tax obligations under stock-based compensation plan

(0.3)


Payment of interest classified as debt


(3.5)

Payment of principal to redeem 8.25% Notes


(74.3)

Cash used in financing activities

(0.3)


(52.6)





Effect of exchange rate changes on cash, cash equivalents and restricted cash

(0.3)


(0.1)





Decrease in cash, cash equivalents and restricted cash

(58.9)


(18.3)

Cash, cash equivalents and restricted cash, beginning of period

1,960.1


704.0

Cash, cash equivalents and restricted cash, end of period

$                  1,901.2


$                     685.7


Three Months Ended March 31,


2026


2025





Supplemental cash flow disclosures:




Cash paid for interest


$                          —

Cash paid for income taxes




Federal


$                          —

State


$                          —

Foreign


$                          —





Non-cash activities:




Property, plant and equipment included in accounts payable and accrued liabilities

$                         9.2


$                         0.2

Common stock withheld for tax obligations under stock-based compensation plan

$                          —


$                         0.3

CENTRUS ENERGY CORP.
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited; in millions, except share and per share data)


March 31, 
 2026


December 31, 
 2025

ASSETS




Current assets:




Cash and cash equivalents

$                  1,868.2


$                  1,957.2

Accounts receivable

41.8


30.7

Inventories

336.0


322.9

Deferred costs associated with deferred revenue

37.0


40.9

Other current assets

12.4


11.9

Total current assets

2,295.4


2,363.6

Property, plant and equipment, net of accumulated depreciation of $7.1 million and
  $6.7 million as of March 31, 2026 and December 31, 2025, respectively

59.5


29.5

Deposits for financial assurance

32.8


2.7

Intangible assets, net

19.4


21.2

Deferred tax assets

19.5


21.9

Other long-term assets

6.6


7.0

Total assets

$                  2,433.2


$                  2,445.9





LIABILITIES AND STOCKHOLDERS' EQUITY




Current liabilities:




Accounts payable and accrued liabilities

$                       49.5


$                       41.6

Payables under inventory purchase agreements

65.7


18.5

Inventories owed to customers and suppliers

170.8


192.7

Deferred revenue and advances from customers

112.8


131.1

Short-term inventory loans

2.5


38.9

Current debt


Total current liabilities

401.3


422.8

Long-term debt

1,176.1


1,174.8

Postretirement health and life benefit obligations

70.4


72.2

Pension benefit liabilities

2.9


3.0

Advances from customers


Long-term inventory loans


Other long-term liabilities

7.3


8.0

Total liabilities

1,658.0


1,680.8





Stockholders' equity:




Preferred stock, par value $1.00 per share, 20,000,000 shares authorized




Series A Participating Cumulative Preferred Stock, none issued


Series B Senior Preferred Stock, none issued


Class A Common Stock, par value $0.10 per share, 70,000,000 shares authorized,
  18,952,387 and 18,945,365 shares issued and outstanding as of March 31, 2026
  and December 31, 2025, respectively

1.9


1.9

Class B Common Stock, par value $0.10 per share, 30,000,000 shares authorized,
  719,200 shares issued and outstanding as of March 31, 2026 and December 31,
  2025

0.1


0.1

Excess of capital over par value

762.4


762.3

Retained earnings

11.5


1.5

Accumulated other comprehensive loss

(0.7)


(0.7)

Total stockholders' equity

775.2


765.1

Total liabilities and stockholders' equity

$                  2,433.2


$                  2,445.9

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/centrus-reports-first-quarter-2026-results-302763250.html

SOURCE Centrus Energy Corp.

FAQ

What were Centrus (LEU) Q1 2026 revenue and net income figures?

Centrus reported $76.7 million revenue and GAAP net income of $10.0 million. According to the company, non‑GAAP adjusted net income was $23.5 million, with adjusted EPS of $1.19 basic and $1.05 diluted.

Why did Centrus raise its full‑year 2026 revenue guidance for LEU?

Centrus raised 2026 guidance to $450M–$500M based on commercial progress. According to the company, stronger contract activity and HALEU-related work drove the upward revision and increased near‑term revenue visibility.

What operational investments did Centrus announce for 2026 (LEU)?

Centrus launched a multi‑year centrifuge manufacturing expansion in Oak Ridge and signed Fluor and Palantir partnerships. According to the company, these moves target cost reductions, faster lead times, and industrial scale‑up.

How large is Centrus' backlog and what does it include for LEU (symbol LEU)?

Centrus reported a backlog of $3.9 billion extending to 2040, with approximately $3.1 billion in LEU backlog. According to the company, this includes fixed contracts and ~$2.4 billion in contingent LEU sales commitments.

What guidance did Centrus give for 2026 capital deployment and hiring?

Centrus expects total capital deployment of $350M–$500M and at least 100 net new hires each for Oak Ridge and Piketon facilities. According to the company, this reflects accelerated investment in manufacturing build‑out.